NCT06183931: An ongoing trial by Alexion Pharmaceuticals, Inc.
This trial is ongoing. It must report results 2 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06183931 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 11, 2024 |
| Completion date | June 7, 2027 |
| Required reporting date | June 6, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |